Request a representative visit or G7 15 Day or G7 samples
CGM Frequency and Glycemic Control Among Patients with Type 2 Diabetes
Summary
Summary of research analyzing continuous glucose monitoring (CGM) usage frequency and glycemic data over 12 months in adults with type 2 diabetes.
Background
People with type 2 diabetes may experience different glycemic outcomes based on how consistently they use CGM. This retrospective analysis of 9,258 adults with type 2 diabetes evaluated the relationship between CGM use over 12 months and changes in A1C across multiple treatment regimens.
Main outcomes
- Greater CGM use was associated with greater A1C reduction, with the most durable improvements observed in people using CGM for more than 270 days.
- The first six months after CGM initiation emerged as an important period for establishing long-term glycemic benefit.
- Improved glycemic outcomes were observed across treatment regimens, including non-insulin therapies, basal insulin, and prandial insulin. CGM use alongside GLP-1RA, SGLT-2i, basal insulin, and prandial insulin was associated with greater A1C reductions than medication alone.
What this means for your practice
Greater CGM use was associated with greater A1C reduction, with the most durable improvements observed in people using CGM for more than 270 days.
- The first six months after CGM initiation emerged as an important period for establishing long-term glycemic benefit.
- Improved glycemic outcomes were observed across treatment regimens, including non-insulin therapies, basal insulin, and prandial insulin. CGM use alongside GLP-1RA, SGLT-2i, basal insulin, and prandial insulin was associated with greater A1C reductions than medication alone.
References
Hirsch IB, Garg SK, Repetto E, et al. Continuous Glucose Monitoring Frequency and Glycemic Control in People With Type 2 Diabetes. JAMA Netw Open. 2025;8(10):e2539278. Published 2025 Oct 1. doi:10.1001/jamanetworkopen.2025.39278
For a deeper dive on this topic, visit GlucoseTech
